About
About Tibet AIM Pharm. Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; medicines for gynecology and obstetrics; and Gualoupi injection, Nalmefene hydrochloride injection, and Carbetocin injection. It also provides Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems. Tibet AIM Pharm. Inc. was founded in 2003 and is based in Lhasa, China.
Visit company website
5 years, 5 months ago
Tibet AIM Pharm. Inc is currently in a long term downtrend where the price is trading 6.3% below its 200 day moving average.
From a valuation standpoint, the stock is 73.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.6.
Tibet AIM Pharm. Inc's total revenue rose by 31.2% to $155M since the same quarter in the previous year.
Its net income has increased by 6.1% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 119.0% to $17M since the same quarter in the previous year.
Based on the above factors, Tibet AIM Pharm. Inc gets an overall score of 4/5.